The information in this section is intended for visitors outside the United States.
Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine
European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment
Gilead Sciences Announces Third Quarter 2015 Dividend
Gilead Sciences Announces Second Quarter 2015 Financial Results
Gilead Announces Executive Promotions
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
2014 Annual Review